62 results
8-K
EX-99.1
GRTS
Gritstone Bio Inc
9 May 24
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
4:07pm
in metastatic microsatellite-stable colorectal cancer (MSS-CRC) demonstrated a favorable trend in progression-free survival (PFS). Long-term circulating … , respectively.
oGritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
In April 2024, Gritstone presented
8-K
EX-1.1
GRTS
Gritstone Bio Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:23pm
is given in the Registration Statement and the Pricing Prospectus and the Prospectus, there has not been (x) any change in the long-term debt or capital … Prospectus) or long-term debt of the Company and its subsidiaries taken as a whole or any change or effect, or any development involving
424B5
GRTS
Gritstone Bio Inc
2 Apr 24
Prospectus supplement for primary offering
5:20pm
progression-free survival (“PFS”), long-term circulating tumor DNA (“ctDNA”) and tolerability data from the Phase 2 portion of our randomized, open-label … molecular
S-2
response rates across arms (GRANITE and control). Conversely, long-term ctDNA data demonstrated the expected correlation of ctDNA
424B5
mvyzoy
1 Apr 24
Prospectus supplement for primary offering
4:43pm
8-K
f0rtjmhjj5mlq
1 Apr 24
Other Events
4:08pm
8-K
EX-99.1
coy35b3gufb
5 Mar 24
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
4:08pm
8-K
EX-99.1
pztse2qrqya
8 Nov 23
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
iuekw38
9 Aug 23
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
4:08pm
8-K
EX-99.1
b6txgli3
11 May 23
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:09pm